You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
映恩生物-B(9606.HK)首日上市高開91.33%
格隆匯 04-15 09:30
港股映恩生物-B(9606.HK)今日首日上市,高開91.33%報181港元,盤前成交7.82億港元。該股IPO定價爲94.6港元,公開發售階段獲115.14倍認購,經回補、重新分配後,公開發售的發售股份最終數目爲753.58萬股股份,佔發售股份總數的約43.48%;國際發售股份最終數目爲979.65萬股股份,相當於發售股份總數的56.52%。映恩生物成立於2019年,總部位於上海,是一家專注於新一代抗體偶聯藥物(ADC)研發的創新生物製藥企業,致力於爲癌症和自身免疫性疾病等患者研發新一代ADC創新藥物。映恩生物的收入主要來自對外許可及合作協議。招股書顯示,2023年和2024年營業收入分別爲人民幣17.87億和19.41億元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account